This is a competing renewal application for the New England Consortium Node (NECN), led by Kathleen Carroll, Ph.D., of Yale and Roger Weiss, M.D., of Harvard. The NECN has a track record of outstanding productivity in the Clinical Trials Network (CTN), with leadership of 4 highly successful trials, high levels of study participation, excellent recruitment and retention, and 64 peer-reviewed publications from CTN trial data during the current funding period. NECN investigators have first-authored all 3 of the most highly-cited CTN publications and all 4 CTN publications cited most often per year. The overarching goal of the NECN is to develop effective and sustainable interventions for substance use disorders that can be delivered in multiple healthcare settings, addressing substance use in all its diversity. Achieving this goal will entail 1) building on single-site efficacy trials to conduct multi-site effectivenes studies of promising interventions; 2) improving interventions with promising but modest results to date; and 3) developing innovative approaches for prevalent problems with no clearly established standard of care, or with suboptimal results in early studies (e.g., screening and brief intervention for drug use in primary care). To address these goals, the NECN has added 1) local, regional, and national hospital-based and primary care networks that cover millions of individuals, and 2) investigators from 7 New England universities who have conducted seminal work in addiction medicine and innovative technology (Drs. Fiellin, Higgins, Marsch, O'Connor, Saitz, Samet). The NECN research agenda demonstrates its capacity to develop and implement novel approaches to improve treatment for substance users wherever they contact the healthcare system. Proposed studies build on the previous work of NECN investigators and include, among others: 1. Screening and brief intervention (SBI) vs. repeated BIs vs. computer-based cognitive-behavioral therapy for risky drug use in primary care (Saitz, Carroll); 2. Financial incentives for pregnant smokers in obstetrical practice (Higgins); 3. Buprenorphine initiation in the emergency department vs. facilitated referral for opioid dependent patients (Fiellin, D'Onofrio); and 4. Use of peer navigators to enhance treatment retention among opioid dependent patients started on buprenorphine during hospitalization (Liebschutz, Stein).

Public Health Relevance

The National Drug Abuse Treatment Clinical Trials Network (CTN) conducts clinically relevant drug abuse research in real-world settings, with an increasing emphasis on conducting studies in general medical settings. The New England Consortium Node of the CTN is poised to foster the development of effective, scalable, and sustainable interventions for individuals with a variety of substance use problems, so that they can be offered effective treatment in whatever healthcare setting they enter, thus improving overall public health.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Dobbins, Ronald
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mclean Hospital
United States
Zip Code
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Tomko, Rachel L; Baker, Nathaniel L; McClure, Erin A et al. (2018) Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend 182:1-7
Fitzmaurice, Garrett M; Lipsitz, Stuart R; Weiss, Roger D (2018) Sensitivity analysis for non-monotone missing binary data in longitudinal studies: Application to the NIDA collaborative cocaine treatment study. Stat Methods Med Res :962280218794725
Decker, Suzanne E; Morie, Kristen P; Malin-Mayo, Bo et al. (2018) Positive and negative affect in cocaine use disorder treatment: Change across time and relevance to treatment outcome. Am J Addict :
Campbell, Aimee N C; Barbosa-Leiker, Celestina; Hatch-Maillette, Mary et al. (2018) Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict 27:465-470
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
McHugh, R Kathryn; Votaw, Victoria R; Sugarman, Dawn E et al. (2018) Sex and gender differences in substance use disorders. Clin Psychol Rev 66:12-23
Korthuis, P Todd; Edelman, E Jennifer (2018) Substance use and the HIV care continuum: important advances. Addict Sci Clin Pract 13:13
Fitzmaurice, Garrett M; Lipsitz, Stuart R; Weiss, Roger D (2017) Statistical considerations in the choice of endpoint for drug use disorder trials. Drug Alcohol Depend 181:219-222
Carroll, Kathleen M; Kiluk, Brian D (2017) Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again. Psychol Addict Behav 31:847-861

Showing the most recent 10 out of 23 publications